Table 2. Characteristics of breast cancer cases received neoadjuvant chemotherapy after diagnosis.
| Variable | Number |
|---|---|
| Female, n (%) | 180 [100] |
| Age, mean ± SD, years | 48.2±11.0 |
| Menopausal status | |
| Pre-menopausal | 102 (56.67) |
| Post-menopausal | 78 (43.33) |
| Tumor location | |
| Left | 94 (52.22) |
| Right | 86 (47.78) |
| Biopsy date (year), n (%) | |
| ~2014 | 23 (12.78) |
| 2015 | 43 (23.89) |
| 2016 | 79 (43.89) |
| 2017 | 35 (19.44) |
| Histopathology, n (%) | |
| Invasive breast cancer | 180 [100] |
| Clinical T stage, n (%) | |
| cT1 | 21 (11.67) |
| cT2 | 139 (77.22) |
| cT3 | 20 (11.11) |
| Clinical N stage, n (%) | |
| cN0 | 67 (37.22) |
| cN1 | 106 (58.89) |
| cN2 | 7 (3.89) |
| Clinical TNM stage, n (%) | |
| I | – |
| II | 158 (87.78) |
| III | 22 (12.22) |
| Biopsy ER status, n (%) | |
| Positive | 120 (66.67) |
| Negative | 60 (33.33) |
| Biopsy PR status, n (%) | |
| Positive | 96 (53.33) |
| Negative | 84 (46.67) |
| Biopsy HER2 status, n (%) | |
| Positive | 72 (40.00) |
| Negative | 108 (60.00) |
| Biopsy Ki-67, n (%) | |
| <14% | 9 (5.00) |
| 14–50% | 130 (72.22) |
| >50% | 41 (22.78) |
| Biopsy molecular subtype, n (%) | |
| Luminal A | 8 (4.44) |
| Luminal B/HER2 negative | 71 (39.44) |
| Luminal B/HER2 positive | 41 (22.78) |
| HER2 positive | 31 (17.22) |
| Triple negative | 29 (16.11) |
ER, estrogen receptor; PR, progesterone receptor.